Eli Lilly and Company - Total Other Finance Cost
Eli Lilly and Company's Fiscal Year is From January To December - All Figures are in USD, Millions.
The item "Total-Other-Finance-Cost" stands at 89.70 Million United States Dollars for the trailing twelve months (TTM) period ending 06/30/2024.'
Regarding the One-Year-Change of the series, the current value constitutes an increase of 22.30 Million United States Dollars compared to the value the year prior.
The 1 year change is 22.30 Million United States Dollars.
The 3 year change is -65.90 Million United States Dollars.
The 5 year change is 154.50 Million United States Dollars.
The 10 year change is 242.50 Million United States Dollars.
The Serie's change in United States Dollars from it's minimum value, on 12/31/2018, to it's latest available value, on 06/30/2024, is +353.20 Million.
The Serie's change in United States Dollars from it's maximum value, on 09/30/2023, to it's latest available value, on 06/30/2024, is -67.40 Million.
Total Other Finance Cost for Related Companies:
| Logo | Name | Market Cap (USD) |
|---|---|---|
 | Johnson & Johnson - Total Other Finance Cost | 486,508,953,600.00 |
 | AbbVie Inc - Total Other Finance Cost | 399,570,305,024.00 |
 | Roche Holding AG - Total Other Finance Cost | 317,433,206,677.55 |
 | AstraZeneca PLC - Total Other Finance Cost | 280,205,508,085.11 |
 | Novartis AG - Total Other Finance Cost | 255,096,620,580.91 |